5 Access Themes That Will Shape the Dialogue at Asembia 2025

As the specialty drug landscape evolves at breakneck speed, market access is no longer just a box to check - it's a high-stakes, ever-evolving priority that pharma must continuously rethink. The industry is facing mounting pressure to prove value, streamline the patient experience, and reduce access friction in a world of fragmented coverage, financial strain, and digital disruption.

At the Asembia 2025 (AX25) Summit, these realities will take center stage - not as future trends, but as current tensions shaping how therapies reach the patients who need them. The following five forces are driving the access conversation forward and redefining how pharma must operate.

Value Is No Longer Just an Argument - It's an Operational Imperative

Today, access teams must go beyond articulating value - they must demonstrate it in motion. With heightened pressure to reduce costs through escalating contracts and payers demanding more real-world evidence post-approval to maintain access, value frameworks are evolving from marketing assets into execution blueprints.

Demonstrating real-world outcomes, total cost-of-care impact, and longitudinal data is now critical - especially in high-investment areas like oncology, rare diseases, and cell and gene therapies. But the approach isn't one-size-fits-all. The structure and importance of these elements vary by territory and must be understood not only within the local jurisdiction but also in terms of the direct and indirect influence they may have on other jurisdictions.

This year’s Asembia Conference features several sessions on alternative contracting models and value-based care. Success will depend on choosing the right value approach based on each asset's profile and place within the broader portfolio. Strategic flexibility will be the new currency of access

AI Is No Longer Emerging—It's Embedded

Artificial intelligence is rapidly becoming part of the access infrastructure. From automating prior authorizations and predicting formulary wins to segmenting payer accounts and optimizing field content, AI is quietly transforming commercial access operations.

But adoption is only half the equation - integration is now the challenge. AI must plug into HUB systems, SP workflows, CRM platforms, and provider touchpoints to truly move the needle.

Expect discussions at the Asembia Conference to move beyond AI hype and into how organizations are integrating these capabilities for measurable speed, efficiency, and access activation.

The Digital HUB Is Becoming the New Brand Touchpoint

As therapy journeys grow more complex, the digital HUB is emerging as the command center for access, support, and service orchestration. Legacy models built on manual processes and reactive call centers are giving way to intelligent platforms that proactively manage patient onboarding, benefits navigation, and adherence continuity.

These HUBs don't just enable faster therapy starts—they generate critical data that informs payer strategy, patient services, and product performance.

With sessions this year exploring digital engagement, HUB innovation, and SP collaboration, it's clear that connected patient experiences are no longer optional - they're expected.

Payer Engagement Requires Precision, Not Just Presence

Payer decision-making is increasingly fragmented. What used to be centralized, relationship-driven models are being replaced by regional variances, therapeutic subcommittees, and evolving benefit designs. The traditional access playbook—mass outreach, generic decks, infrequent updates—no longer works.

What's needed now is precision engagement: highly tailored content, data-driven messaging, and real-time adaptability based on shifting coverage signals.

Expect discussions around payer personalization, account strategy, and digital field enablement to take on renewed urgency at this year's summit.

Affordability Is Now a Strategic Risk Factor

Patient affordability has always been a key component of market access - and today, it plays an even greater role in driving product adoption. As copay accumulators, insurance restrictions, and rising out-of-pocket costs become more common, financial barriers are leading to increased therapy abandonment - even when access is technically approved.

Despite local legislation aimed at curbing certain insurance practices, cost shifting remains a persistent challenge.

Forward-looking pharma companies are tackling this head-on by embedding patient affordability strategies into launch planning. This includes predictive financial assessments, more targeted copay programs, and even alternative financing models.

Sessions at this year's Asembia Conference will highlight the growing urgency to treat affordability not as a downstream issue, but as a core pillar of any access strategy.

Why These Conversations Matter Now

Each of these forces represent pressure points where pharma must evolve to remain effective. Together, they are shaping a new model of access: personalized, AI-enabled, patient affordability-conscious, and deeply integrated into patient and provider workflows. Asembia 2025 is where these conversations converge.

Let's Connect at Asembia 2025

Indegene is proud to be part of this year’s Asembia conference, collaborating with peers and partners to shape access strategies that are built for today—and ready for what’s next. Visit us at Booth #2022 or schedule a conversation to explore how we’re helping pharma move from complexity to clarity in access execution.